Market capitalization | $3.16m |
Enterprise Value | $2.36m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.04 |
P/S ratio (TTM) P/S ratio | 0.05 |
P/B ratio (TTM) P/B ratio | 0.20 |
Revenue growth (TTM) Revenue growth | -47.53% |
Revenue (TTM) Revenue | $58.62m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Medigus Ltd Sponsored ADR:
1 Analyst has issued a forecast Medigus Ltd Sponsored ADR:
Jun '24 |
+/-
%
|
||
Revenue | 59 59 |
48%
48%
|
|
Gross Profit | 7.89 7.89 |
53%
53%
|
|
EBITDA | -5.31 -5.31 |
15%
15%
|
EBIT (Operating Income) EBIT | -11 -11 |
13%
13%
|
Net Profit | -16 -16 |
11%
11%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Medigus Ltd. is a medical device company, which engages in the research and development, manufacture, and sale of endosurgical tools and instruments. It specializes in the area of Gastroesophageal reflux disease. Its product MUSE System offers minimal invasive endoscopic devices and procedures for gastric surgery. The company was founded by Elazar Sonnenschein on December 9, 1999 and is headquartered in Omer, Israel.
Head office | Israel |
CEO | Liron Carmel |
Employees | 84 |
Founded | 1999 |
Website | www.medigus.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.